Review



artificial intelligence–based software approach  (Cleerly Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Cleerly Inc artificial intelligence–based software approach
    Artificial Intelligence–Based Software Approach, supplied by Cleerly Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/artificial-intelligence-based+approach/ai+based+software+tool/pmc12190865-107-2-17
    Average 90 stars, based on 1 article reviews
    artificial intelligence–based software approach - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Computed Tomography:

    Article Title: AI-Quantitative CT Coronary Plaque Features Associate With a Higher Relative Risk in Women: CONFIRM2 Registry
    Article Snippet: Artificial intelligence–enabled technology (Cleerly, Inc, Denver) was applied to analyze the CCTA images.

    Article Title: Diagnostic accuracy in coronary CT angiography analysis: artificial intelligence versus human assessment.
    Article Snippet: The CCTA images were analysed using AI- QCT, AI- based software service from Cleerly (Denver, Colorado, USA), which has received clearance from the US Food and Drug Administration.

    Article Title: Racial differences in atherosclerosis and coronary plaque characteristics using enhanced AI quantification (RACE-AI).
    Article Snippet: Cardiac computed tomography angiography (CCTA) has become a cornerstone in cardiovascular risk assessment, allowing for the quantification of coronary artery disease (CAD) burden and characterization of high-risk plaque features associated with adverse outcomes.. Coronary artery calcium (CAC) scoring, utilizing the Agatston method, has been extensively validated as a predictor of cardiovascular events, with calcified plaques considered more stable and non-calcified plaques (NCP) linked to heightened cardiovascular risk.1,2 The SCOT-HEART trial highlighted that low-attenuation non-calcified plaques (>4 % volume) increased the risk of myocardial infarction fivefold, independent of traditional risk factors.3 However, racial differences in CAC and plaque characteristics remain an area of ongoing investigation.. Studies have suggested racial disparities in CAC burden, with lower CAC prevalence observed in Black, Hispanic, and Chinese populations compared to White individuals.4 The Multi-Ethnic Study of Atherosclerosis (MESA) established that despite differences in CAC burden among racial groups, CAC remains a robust predictor of cardiovascular risk across populations.5 However, data on racial differences in NCP volume are limited, particularly with advanced AI-enabled CCTA analysis.

    Article Title: Fractional Flow Reserve Relates Stronger to Coronary Plaque Burden Than Nonhyperemic Pressure Indexes
    Article Snippet: A fully automatic US Food and Drug Administration– approved AI- based software approach (Cleerly Inc) was used to analyze the CCTA.15 The AI- QCT software uses validated convolutional neural networks for image quality assessment, coronary segmentation, vessel contour determination, lumen wall evaluation, and plaque characterization and quantification.

    Article Title: Artificial intelligence quantification and experienced reader computed tomography analysis for differentiating normal from minimally and mildly diseased coronary arteries: an early real-world compatibility study.
    Article Snippet: 1 University of Kentucky-King’s Daughters Medical Center, 2201 Lexington Ave, Ashland, KY 41101, USA 2 Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, USA 3 Minneapolis Heart Institute Foundation, Minneapolis, MN, USA 4 Cleerly Inc, Denver, CO, USA Abstract Differentiating normal from minimally and mildly diseased coronary arteries on coronary computed tomographic angiography (CCTA) is crucial, impacting treatment decisions due to the extremely low coronary artery event risk associated with the former.. Artificial intelligence quantitative computed tomographic (AI-QCT) can potentially identify subclinical atherosclerosis in cases deemed normal by reader interpretation.. We aimed to evaluate AI-QCT’s ability to distinguish reader-determined normal coronary arteries from those with minimal and mild diseased on CCTA.

    Article Title: Fractional Flow Reserve Relates Stronger to Coronary Plaque Burden Than Nonhyperemic Pressure Indexes
    Article Snippet: A fully automatic US Food and Drug Administration–approved AI‐based software approach (Cleerly Inc) was used to analyze the CCTA.

    Article Title: Microvascular resistance reserve in relation to total and vessel-specific atherosclerotic burden
    Article Snippet: A US Food and Drug Administration–approved artificial intelligence (AI)–based software approach (Cleerly Inc.) was used to analyse the CCTA.

    Article Title: Coronary computed tomography angiography to guide percutaneous coronary intervention: Expert opinion from a SCAI/SCCT roundtable.
    Article Snippet: Coronary computed tomography angiography (CCTA) has emerged as an important tool for planning percutaneous coronary intervention (PCI).. While it has traditionally been employed for diagnostic purposes, increasing evidence and real-world experience suggest that CCTA can be used for the pre-procedural planning of PCI and inform patient triage, shared decision-making, case complexity, and resource use.. This approach mirrors how computed tomography angiography is routinely used to plan structural interventions.

    Software:

    Article Title: AI-Quantitative CT Coronary Plaque Features Associate With a Higher Relative Risk in Women: CONFIRM2 Registry
    Article Snippet: Artificial intelligence–enabled technology (Cleerly, Inc, Denver) was applied to analyze the CCTA images.

    Article Title: Diagnostic accuracy in coronary CT angiography analysis: artificial intelligence versus human assessment.
    Article Snippet: The CCTA images were analysed using AI- QCT, AI- based software service from Cleerly (Denver, Colorado, USA), which has received clearance from the US Food and Drug Administration.

    Article Title: Racial differences in atherosclerosis and coronary plaque characteristics using enhanced AI quantification (RACE-AI).
    Article Snippet: Cardiac computed tomography angiography (CCTA) has become a cornerstone in cardiovascular risk assessment, allowing for the quantification of coronary artery disease (CAD) burden and characterization of high-risk plaque features associated with adverse outcomes.. Coronary artery calcium (CAC) scoring, utilizing the Agatston method, has been extensively validated as a predictor of cardiovascular events, with calcified plaques considered more stable and non-calcified plaques (NCP) linked to heightened cardiovascular risk.1,2 The SCOT-HEART trial highlighted that low-attenuation non-calcified plaques (>4 % volume) increased the risk of myocardial infarction fivefold, independent of traditional risk factors.3 However, racial differences in CAC and plaque characteristics remain an area of ongoing investigation.. Studies have suggested racial disparities in CAC burden, with lower CAC prevalence observed in Black, Hispanic, and Chinese populations compared to White individuals.4 The Multi-Ethnic Study of Atherosclerosis (MESA) established that despite differences in CAC burden among racial groups, CAC remains a robust predictor of cardiovascular risk across populations.5 However, data on racial differences in NCP volume are limited, particularly with advanced AI-enabled CCTA analysis.

    Article Title: Fractional Flow Reserve Relates Stronger to Coronary Plaque Burden Than Nonhyperemic Pressure Indexes
    Article Snippet: A fully automatic US Food and Drug Administration– approved AI- based software approach (Cleerly Inc) was used to analyze the CCTA.15 The AI- QCT software uses validated convolutional neural networks for image quality assessment, coronary segmentation, vessel contour determination, lumen wall evaluation, and plaque characterization and quantification.

    Article Title: Artificial intelligence quantification and experienced reader computed tomography analysis for differentiating normal from minimally and mildly diseased coronary arteries: an early real-world compatibility study.
    Article Snippet: 1 University of Kentucky-King’s Daughters Medical Center, 2201 Lexington Ave, Ashland, KY 41101, USA 2 Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, USA 3 Minneapolis Heart Institute Foundation, Minneapolis, MN, USA 4 Cleerly Inc, Denver, CO, USA Abstract Differentiating normal from minimally and mildly diseased coronary arteries on coronary computed tomographic angiography (CCTA) is crucial, impacting treatment decisions due to the extremely low coronary artery event risk associated with the former.. Artificial intelligence quantitative computed tomographic (AI-QCT) can potentially identify subclinical atherosclerosis in cases deemed normal by reader interpretation.. We aimed to evaluate AI-QCT’s ability to distinguish reader-determined normal coronary arteries from those with minimal and mild diseased on CCTA.

    Article Title: Fractional Flow Reserve Relates Stronger to Coronary Plaque Burden Than Nonhyperemic Pressure Indexes
    Article Snippet: A fully automatic US Food and Drug Administration–approved AI‐based software approach (Cleerly Inc) was used to analyze the CCTA.

    Article Title: Microvascular resistance reserve in relation to total and vessel-specific atherosclerotic burden
    Article Snippet: A US Food and Drug Administration–approved artificial intelligence (AI)–based software approach (Cleerly Inc.) was used to analyse the CCTA.

    Article Title: Coronary computed tomography angiography to guide percutaneous coronary intervention: Expert opinion from a SCAI/SCCT roundtable.
    Article Snippet: Coronary computed tomography angiography (CCTA) has emerged as an important tool for planning percutaneous coronary intervention (PCI).. While it has traditionally been employed for diagnostic purposes, increasing evidence and real-world experience suggest that CCTA can be used for the pre-procedural planning of PCI and inform patient triage, shared decision-making, case complexity, and resource use.. This approach mirrors how computed tomography angiography is routinely used to plan structural interventions.



    Similar Products

    90
    Cleerly Inc artificial intelligence (ai)–based software approach
    Artificial Intelligence (Ai)–Based Software Approach, supplied by Cleerly Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/artificial-intelligence-based+approach/ai+based+software+tool/pmc11879247-104-4-11
    Average 90 stars, based on 1 article reviews
    artificial intelligence (ai)–based software approach - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Cleerly Inc artificial intelligence–based software approach
    Artificial Intelligence–Based Software Approach, supplied by Cleerly Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/artificial-intelligence-based+approach/ai+based+software+tool/pmc12190865-107-2-17
    Average 90 stars, based on 1 article reviews
    artificial intelligence–based software approach - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Omics Data Automation artificial intelligence (ai)-based systems biology approaches
    Artificial Intelligence (Ai) Based Systems Biology Approaches, supplied by Omics Data Automation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/artificial-intelligence-based+approach/artificial+intelligence++ai++based+systems+biology+approaches/pm39127104-343-2-12
    Average 90 stars, based on 1 article reviews
    artificial intelligence (ai)-based systems biology approaches - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Cleerly Inc artificial intelligence– based software approach
    Artificial Intelligence– Based Software Approach, supplied by Cleerly Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/artificial-intelligence-based+approach/ai+based+software+tool/pm39152960-47-2-19
    Average 90 stars, based on 1 article reviews
    artificial intelligence– based software approach - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Voronoi Health Analytics artificial-intelligence-based segmentation approach
    Artificial Intelligence Based Segmentation Approach, supplied by Voronoi Health Analytics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/artificial-intelligence-based+approach/artificial+intelligence+based+segmentation+approach/pm38896951-95-5-0
    Average 90 stars, based on 1 article reviews
    artificial-intelligence-based segmentation approach - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Symptoma GmbH artificial intelligence-based approach
    Artificial Intelligence Based Approach, supplied by Symptoma GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/artificial-intelligence-based+approach/artificial+intelligence+based+approach/pmc10160659-45-2-2
    Average 90 stars, based on 1 article reviews
    artificial intelligence-based approach - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Atomwise Inc artificial intelligence-based drug discovery approaches
    Artificial Intelligence Based Drug Discovery Approaches, supplied by Atomwise Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/artificial-intelligence-based+approach/artificial+intelligence+drug+discovery/pm33184478-171-11-3
    Average 90 stars, based on 1 article reviews
    artificial intelligence-based drug discovery approaches - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Martin Marietta artificial-intelligence-based approach
    Artificial Intelligence Based Approach, supplied by Martin Marietta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/artificial-intelligence-based+approach/artificial+intelligence+based+approach/pmc04943745-42-15-4
    Average 90 stars, based on 1 article reviews
    artificial-intelligence-based approach - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results